Carbapenem resistance in a clinical isolate of Citrobacter freundii
- PMID: 9371332
- PMCID: PMC164127
- DOI: 10.1128/AAC.41.11.2352
Carbapenem resistance in a clinical isolate of Citrobacter freundii
Abstract
Carbapenem resistance was studied in two sets of Citrobacter freundii strains: (i) strain CFr950, resistant to imipenem (MIC, 16 microg/ml) and isolated in vivo during imipenem therapy, and strain CFr950-Rev, the spontaneous, imipenem-susceptible revertant of CFr950 selected in vitro, and (ii) strains CFr801 and CFr802, two imipenem-resistant mutants selected in vitro from the susceptible clinical isolate CFr800. In all strains, whether they were imipenem-susceptible or -resistant strains, production of the cephalosporinase was derepressed and their Km values for cephaloridine were in the range of 128 to 199 microM. No carbapenemase activity was detected in vitro. The role of cephalosporinase overproduction in the resistance was demonstrated after introduction of the ampD gene which decreased the level of production of cephalosporinase at least 250-fold and resulted in an 8- to 64-fold decrease in the MICs of the carbapenems. The role of reduced permeability in the resistance was suggested by the absence, in CFr950 and CFr802, of two outer membrane proteins (the 42- and 40-kDa putative porins whose levels were considerably decreased in CFr801) and the reappearance of the 42-kDa protein in imipenem-susceptible strain CFr950-Rev. This role was confirmed after introduction of the ompF gene of Escherichia coli into the CFr strains, which resulted in 8- to 16-fold decreases in the MICs of carbapenems for CFr802 and CFr950. We infer from these results that the association of reduced, porin-mediated permeability with high-level cephalosporinase production, observed previously in other gram-negative bacteria, may also confer carbapenem resistance on C. freundii.
Similar articles
-
Association of two resistance mechanisms in a clinical isolate of Enterobacter cloacae with high-level resistance to imipenem.Antimicrob Agents Chemother. 1991 Jun;35(6):1093-8. doi: 10.1128/AAC.35.6.1093. Antimicrob Agents Chemother. 1991. PMID: 1929248 Free PMC article.
-
High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression.J Med Microbiol. 2008 Mar;57(Pt 3):332-337. doi: 10.1099/jmm.0.47576-0. J Med Microbiol. 2008. PMID: 18287296
-
Analyses of a Ceftazidime-Avibactam-Resistant Citrobacter freundii Isolate Carrying blaKPC-2 Reveals a Heterogenous Population and Reversible Genotype.mSphere. 2018 Sep 26;3(5):e00408-18. doi: 10.1128/mSphere.00408-18. mSphere. 2018. PMID: 30258039 Free PMC article.
-
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Drugs. 2018. PMID: 29230684 Review.
-
Bacterial resistance: a worldwide problem.Diagn Microbiol Infect Dis. 1998 Jun;31(2):379-88. doi: 10.1016/s0732-8893(98)00037-6. Diagn Microbiol Infect Dis. 1998. PMID: 9635913 Review.
Cited by
-
Carbapenems: past, present, and future.Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22. Antimicrob Agents Chemother. 2011. PMID: 21859938 Free PMC article. Review.
-
Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2.Antimicrob Agents Chemother. 2003 Dec;47(12):3881-9. doi: 10.1128/AAC.47.12.3881-3889.2003. Antimicrob Agents Chemother. 2003. PMID: 14638498 Free PMC article.
-
A Novel, Integron-Regulated, Class C β-Lactamase.Antibiotics (Basel). 2020 Mar 14;9(3):123. doi: 10.3390/antibiotics9030123. Antibiotics (Basel). 2020. PMID: 32183280 Free PMC article.
-
Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein.Antimicrob Agents Chemother. 1999 May;43(5):1206-10. doi: 10.1128/AAC.43.5.1206. Antimicrob Agents Chemother. 1999. PMID: 10223937 Free PMC article.
-
Meropenem: a review of its use in patients in intensive care.Drugs. 2000 Mar;59(3):653-80. doi: 10.2165/00003495-200059030-00016. Drugs. 2000. PMID: 10776838 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical